102 related articles for article (PubMed ID: 9447960)
1. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
Mühlhauser I; Sawicki PT; Berger M
Diabetologia; 1997 Dec; 40(12):1492-3. PubMed ID: 9447960
[No Abstract] [Full Text] [Related]
2. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
Fasching P
Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
[No Abstract] [Full Text] [Related]
3. Sulfonylureas and the risk of myocardial infarction.
Thisted H; Johnsen SP; Rungby J
Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
[TBL] [Abstract][Full Text] [Related]
4. Diabetes and coronary heart disease.
Engler RL
N Engl J Med; 1998 Dec; 339(23):1715; author reply 1716. PubMed ID: 9867544
[No Abstract] [Full Text] [Related]
5. Sulfonylureas and mortality in diabetic patients after myocardial infarction.
Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A
Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313
[No Abstract] [Full Text] [Related]
6. Relationship between antidiabetic treatment with QT dispersion during acute coronary syndromes in type 2 diabetes: comparison between patients receiving sulfonylureas and insulin.
Tentolouris N; Matsagura M; Psallas M; Chatzizacharias A; Fotia M; Arvanitis M; Katsilambros N
Exp Clin Endocrinol Diabetes; 2005 May; 113(5):298-301. PubMed ID: 15926117
[TBL] [Abstract][Full Text] [Related]
7. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).
Meier JJ; Deifuss S; Klamann A; Schmiegel W; Nauck MA;
Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):344-50. PubMed ID: 14520601
[TBL] [Abstract][Full Text] [Related]
8. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons".
Heine RJ
Horm Metab Res; 1996 Sep; 28(9):522-6. PubMed ID: 8911991
[TBL] [Abstract][Full Text] [Related]
9. Late complications of diabetes mellitus: risk factors in patients on sulfonylureas for more than 10 years.
Hoshi M; Fujita S
Jpn J Med; 1991; 30(6):616-7. PubMed ID: 1798228
[No Abstract] [Full Text] [Related]
10. [40 years of using sulfonylurea derivatives for treatment of diabetes].
Sieradzki J
Przegl Lek; 1996; 53(9):641-6. PubMed ID: 8992529
[TBL] [Abstract][Full Text] [Related]
11. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycemia-induced myocardial infarction: an unusual adverse effect of sulfonylureas.
Chang JH; Tseng CF; Wang JY
Int J Cardiol; 2007 Feb; 115(3):414-6. PubMed ID: 16787671
[TBL] [Abstract][Full Text] [Related]
13. Oral hypoglycemic agents in type II diabetes mellitus.
Lubbos H; Miller JL; Rose LI
Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
[TBL] [Abstract][Full Text] [Related]
14. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
15. Oral sulfonylureas and CV mortality.
Aronow WS
Geriatrics; 2004 Sep; 59(9):45-6, 49. PubMed ID: 15461238
[No Abstract] [Full Text] [Related]
16. Sulphonylureas in the treatment of non-insulin-dependent diabetes.
Ferner RE; Alberti KG
Q J Med; 1989 Nov; 73(271):987-95. PubMed ID: 2695959
[No Abstract] [Full Text] [Related]
17. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
[TBL] [Abstract][Full Text] [Related]
18. Insulin in the early management of diabetic complications.
Miles JM
J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435
[TBL] [Abstract][Full Text] [Related]
19. Exploring the role of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus.
Graham JP; Stam D
Pharm Pract Manag Q; 1997 Oct; 17(3):1-9. PubMed ID: 10173306
[TBL] [Abstract][Full Text] [Related]
20. Combination use of sulfonylureas and insulin in the treatment of noninsulin-dependent diabetes mellitus.
Montgomery PA
Pharmacotherapy; 1992; 12(4):292-9. PubMed ID: 1518728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
